论文部分内容阅读
目的探讨中西医结合治疗对晚期卵巢癌患者的治疗效果及治疗前后免疫学指标的变化。方法选择2012年12月至2014年3月收治的80例晚期卵巢癌患者的临床资料进行回顾性分析。采用常规西医治疗(顺铂、紫杉醇方案化疗)的40例患者为对照组,采用中西医结合治疗(同样化疗基础上联合自拟中药方剂治疗)的40例患者为观察组,两组患者均连续治疗半年。比较两组治疗结束后外周血T细胞亚群(CD3、CD4、CD8、CD4/CD8)和3年生存率、死亡率及复发率等指标。结果治疗后,观察组患者CD3、CD4、CD8、CD4/CD8均较对照组患者改善明显,组间比较差异有统计学意义(P<0.05,P<0.01);随访30个月,观察组患者生存率(92.5%)明显高于对照组患者(72.5%,P<0.05);复发率(10.0%)较对照组(15.0%)有所降低,但差异无统计学意义(P>0.05)。结论采用中西医结合治疗措施,有利于改善晚期卵巢癌患者的免疫学相关指标,延长生存期,提高患者的生存质量。
Objective To explore the treatment of advanced ovarian cancer patients treated with integrated traditional Chinese and western medicine and the changes of immunological indexes before and after treatment. Methods The clinical data of 80 patients with advanced ovarian cancer who were admitted from December 2012 to March 2014 were retrospectively analyzed. Forty patients with conventional Western medicine (cisplatin and paclitaxel chemotherapy) were used as the control group. Forty patients treated with combination of TCM and Western medicine (the same chemotherapy combined with self-made traditional Chinese medicine prescription) were used as the observation group. Both groups were continuous Treatment for six months. The T lymphocyte subsets (CD3, CD4, CD8, CD4 / CD8) and 3-year survival, mortality and relapse rate of the two groups were compared after treatment. Results After treatment, the levels of CD3, CD4, CD8 and CD4 / CD8 in the observation group were significantly improved as compared with those in the control group (P <0.05, P <0.01). The patients in the observation group The survival rate (92.5%) was significantly higher than that of the control group (72.5%, P <0.05). The recurrence rate (10.0%) was lower than that of the control group (15.0%), but the difference was not statistically significant (P> 0.05). Conclusion Integrative treatment with traditional Chinese and Western medicine is conducive to improving the immunological indicators of patients with advanced ovarian cancer, prolong survival and improve the quality of life of patients.